Cheplapharm Arzneimittel GmbH, the German drugmaker, is weighing plans for an initial public offering in what could be one of Europe’s largest share sales of 2021, people familiar with the matter said.
Greifswald-based Cheplapharm is speaking with advisers about a potential listing as soon as this year, the people said, asking not to be identified discussing confidential information. A share sale could value the business at about 7 billion euros to 8 billion euros ($9.5 billion) or more, the people said.
The volume of fundraising from health-care listings globally has nearly doubled this year, as companies ranging from Carlyle Group Inc.-backed testing firm Ortho Clinical Diagnostics Holdings Plc to Beijing-based drug developer Joinn Laboratories (China) Co. rush to tap the market.
By Bloomberg, Manuel Baigorri, Dinesh Nair and Ruth David
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.